President Trump’s tariffs will include imported pharmaceuticals, among other items that will impact the industry.

Future development plans include incorporating AI, expanding connectors, and specializing in additional therapeutic areas.

Approval of Journavx for acute pain marks the first new class of acute pain medication approved by the FDA in over 20 years.

Daniel Vitt, CEO, Immunic Therapeutics, discusses promising results from the Phase Ib trial of IMU-856 in celiac disease.

Approval was based on results from the Phase IIIb FLOW trial, which demonstrated a 24% relative risk reduction in kidney ...

The survey shows voters, regardless of party affiliation, still support vaccines and are concerned about the reduction in ...

A Harvard Business School Healthcare Alumni Association Q&A with Paul Ollinger, one of Facebook’s first 250 employees.

Clinical trials demonstrated that a single dose of Symbravo provides rapid migraine relief, sustains efficacy for up to 48 ...

The Phase III trial builds on findings from prior findings that indicated Anktiva can restore T-cell function and improve ...

Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...

In the United States, the biomedical industry encounters numerous regulatory challenges in conducting nonclinical and ...

A surge in biotech startup out-licensing deals from the country are paving the way for increased IPO and M&A activities.